ESMO 2017: CDK4/6 inhibitors from a patient’s perspective
8 Sep 2017
ESMO 2017: CDK4/6 inhibitors from a patient’s perspective
Emerging targets for the treatment of lung cancer
Targeted therapy for brain and CNS tumours
New treatment avenues in squamous cell carcinoma
Identifying rare mutations in lung cancer
Lung cancer advances beyond PD1
New treatments for acute myeloid leukaemia and lymphoid leukaemia
Current and future prospects in treating multiple myeloma
Changing the standard of care: Metastatic prostate cancer
Celebrating a 10 year partnership: ecancer and the IEO
New drugs on the horizon for pancreatic cancer
WIN 2017 conference review